-
Traders Alert: ContraVir Pharmaceuticals (NASDAQ:CTRV), Twenty-First Century Fox (NASDAQ:FOXA), Potlatch (NASDAQ:PCH), Platform Specialty Products (NYSE:PAH), Apollo Commercial Real Estate Finance (NYSE:ARI)
On 10 March, it was reported ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV) is all set to initiate a pivotal phase 3 study of its lead drug candidate, FV-100, for the prevention of debilitating shingles-associated pain known as post-herpetic neuralgia in the second quarter 2015. On Thursday shares of ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) closed at $3.79. Twenty-First Century…
-
Traders Should Watch: Intrexon Corporation (NYSE:XON), ContraVir Pharmaceuticals (NASDAQ:CTRV), Martin Midstream Partners LP (NASDAQ:MMLP), Galena Biopharma (NASDAQ:GALE), FireEye (NASDAQ:FEYE)
On March 4, Intrexon Corporation (NYSE:XON) announced it has entered into an agreement to acquire Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind theArctic® apple, the world’s first non-browning apple. Through the acquisition, Intrexon expands its food programs to include trees yielding fruit that is more appetizing and convenient for consumers while providing economic…
-
Sizzling Stocks: Avon Products Inc. (NYSE:AVP), ContraVir Pharmaceuticals (NASDAQ:CTRV), Flushing Financial Corp. (NASDAQ:FFIC), Clayton Williams Energy (NYSE:CWEI), Exa Corporation (NASDAQ:EXA)
Analysts at RBC Capital lowered their price target on shares of Avon Products Inc. (NYSE:AVP) from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research note on Friday, February 20th. On Thursday shares of Avon Products Inc. (NYSE:AVP) closed at $9.05. Company’s sales growth for last 5 years was…